نتائج البحث - "Davide Melisi"

91

Target Therapy and Immunotherapy in Gastric Cancer

المؤلفون: Simona Casalino, Davide Melisi, Valeria Merz

المصدر: Gastric Cancer: the 25-year R-Evolution ISBN: 9783030731571

مصطلحات موضوعية: Chemotherapy, business.industry, medicine.medical_treatment, Cancer, Immunotherapy, Precision medicine, medicine.disease, Targeted therapy, Ramucirumab, Regimen, Trastuzumab, Cancer research, medicine, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::bcbd8c6469be6b86492f80abb3f4089dTest
https://doi.org/10.1007/978-3-030-73158-8_28Test

92

A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib

المؤلفون: Davide Melisi, Silvia Pietrobono

المصدر: Cellular and Molecular Gastroenterology and Hepatology
Cellular and Molecular Gastroenterology and Hepatology, Vol 12, Iss 3, Pp 1151-1152 (2021)

مصطلحات موضوعية: Male, DFS, disease-free survival, Drug Resistance, IC50, half maximal inhibitory concentration, RC799-869, DMSO, dimethyl sulfoxide, Mice, GSEA, gene set enrichment analysis, SR, sorafenib-resistant, GEO, Gene Expression Omnibus, NF-κB, nuclear factor kappa B, Original Research, Liver Neoplasms, Gastroenterology, RNA-Binding Proteins, IP, immunoprecipitation, RIP, RNA immunoprecipitation, Hep G2 Cells, Diseases of the digestive system. Gastroenterology, Sorafenib, TAK1, transforming growth factor-β–activated kinase 1, MAP Kinase Kinase Kinases, Up-Regulation, Gene Expression Regulation, Neoplastic, Editorial, Hepatocellular carcinoma, qPCR, quantitative polymerase chain reaction, EMT, epithelial-mesenchymal transition, NASH, nonalcoholic steatohepatitis, IHC, immunohistochemistry, medicine.drug, Carcinoma, Hepatocellular, TAK1, CHX, cycloheximide, Cell Line, Tumor, medicine, Animals, Humans, neoplasms, Cell Proliferation, Hepatology, business.industry, F-Box Proteins, Phenylurea Compounds, Carcinoma, TNF-α, tumor necrosis factor-alpha, Ubiquitination, Membrane Proteins, Hepatocellular, Hepatocellular Carcinoma, medicine.disease, Xenograft Model Antitumor Assays, digestive system diseases, SRRSH, Sir Run Run Shaw Hospital, Drug Resistance, Neoplasm, siRNA, small interfering RNA, Mutation, Proteolysis, Cancer research, Neoplasm, TCGA, The Cancer Genome Atlas, NAFLD, nonalcoholic fatty liver disease, RT, real-time, business, Ubiquitin-Mediated Proteolysis, HCC, hepatocellular carcinoma, OXO, 5z-7-oxozeaenol, DAPI, 4′,6-diamidino-2-phenylindole

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1706b9fa09815f0c5c3763fe5dbd15fTest
https://pubmed.ncbi.nlm.nih.gov/33962073Test

93

Abstract 1064: Targeting stromal autotaxin synergizes with TGF beta inhibition in pancreatic cancer

المؤلفون: Fabio Sabbadini, Monica Bertolini, Domenico Mangiameli, Serena Contarelli, Zoë Johnson, Michael M. Lahn, Silvia Pietrobono, Davide Melisi

المصدر: Cancer Research. 82:1064-1064

مصطلحات موضوعية: Cancer Research, Oncology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::c18b6763792fea4f738e2cf712294efcTest
https://doi.org/10.1158/1538-7445.am2022-1064Test

94

Timing of onset of systemic treatment in asymptomatic patients with metastatic pancreatic cancer

المؤلفون: Simone Augustinus, Hanneke W.M. Van Laarhoven, Geert A. Cirkel, Jan Willem de Groot, Bas Groot Koerkamp, Teresa Macarulla, Davide Melisi, Eileen Mary O'Reilly, Hjalmar van Santvoort, Tara Mackay, Marc G Besselink, Johanna Wilmink

المساهمون: Erasmus MC other, Surgery

المصدر: Journal of Clinical Oncology, 40(16), E16256-E16256. American Society of Clinical Oncology

مصطلحات موضوعية: Cancer Research, Oncology, SDG 3 - Good Health and Well-being

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6de7bf4d7bc2351cd6908fbb83fc0baTest
https://doi.org/10.1200/jco.2022.40.16_suppl.e16256Test

95

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

المؤلفون: Yumin Zhao, Teresa Macarulla, Karim A. Benhadji, Rocio Garcia-Carbonero, M. Lanasa, Davide Melisi, Do Youn Oh, Shawn T. Estrem, Michael Man, Antoine Hollebecque, Emiliano Calvo, Leena Gandhi, Susan C. Guba, Anna M. Varghese, Erkut Borazanci, Valeria Merz, Camilla Zecchetto, Emin Avsar, Ivelina Gueorguieva

المساهمون: Institut Català de la Salut, [Melisi D] Digestive Molecular Clinical Oncology Research Unit, Section of Medical Oncology, Università degli Studi di Verona, Verona, Italy. [Oh DY] Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. [Hollebecque A] Institut Gustave Roussy, Villejuif, France. [Calvo E] START Madrid–CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain. [Varghese A] Memorial Sloan Kettering Cancer Center, New York, New York, USA. [Borazanci E] HonorHealth Research Institute, Scottsdale, Arizona, USA. TGen, Phoenix, Arizona, USA. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Durvalumab, Time Factors, medicine.medical_treatment, Receptor, Transforming Growth Factor-beta Type I, B7-H1 Antigen, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Immunology and Allergy, Other subheadings::/therapeutic use [Other subheadings], Neoplasm Metastasis, Immune Checkpoint Inhibitors, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES], RC254-282, Clinical/Translational Cancer Immunotherapy, Aged, 80 and over, biology, clinical trials as topic, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Antibodies, Monoclonal, Middle Aged, Progression-Free Survival, Europe, 030220 oncology & carcinogenesis, Disease Progression, Quinolines, Molecular Medicine, Female, immunotherapy, Antibody, Signal Transduction, Adult, medicine.medical_specialty, Combination therapy, Immunology, therapies, investigational, 03 medical and health sciences, Refractory, Pharmacokinetics, Internal medicine, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Republic of Korea, Pàncrees - Càncer - Tractament, medicine, Galunisertib, tumor microenvironment, Humans, Protein Kinase Inhibitors, Aged, Pharmacology, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES], business.industry, Otros calificadores::/uso terapéutico [Otros calificadores], diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Immunotherapy, medicine.disease, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], United States, Pancreatic Neoplasms, 030104 developmental biology, tumor biomarkers, biology.protein, Avaluació de resultats (Assistència sanitària), Pyrazoles, business, Progressive disease